LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
26 maart 2020 bijgewerkt door: Boehringer Ingelheim
LUX-Lung 7: A Randomised, Open-label Phase IIb Trial of Afatinib Versus Gefitinib as First-line Treatment of Patients With EGFR Mutation Positive Advanced Adenocarcinoma of the Lung
This is a randomised, open-label, phase IIb trial of afatinib to compare to gefitinib in first-line treatment setting with patients who are having epidermal growth factor receptor mutation positive advanced adenocarcinoma of the lung.
Studie Overzicht
Toestand
Voltooid
Conditie
Interventie / Behandeling
Studietype
Ingrijpend
Inschrijving (Werkelijk)
319
Fase
- Fase 2
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
New South Wales
-
Camperdown, New South Wales, Australië, 2050
- Chris OBrien Lifehouse
-
Kogarah, New South Wales, Australië, 2217
- St George Hospital
-
-
Queensland
-
Chermside, Queensland, Australië, 4032
- The Prince Charles Hospital
-
South Brisbane, Queensland, Australië, 4101
- Haematology & Oncology Clinics of Australasia (HOCA)
-
-
Victoria
-
Box Hill, Victoria, Australië, 3128
- Box Hill Hospital
-
Heidelberg, Victoria, Australië, 3084
- Austin Health
-
-
Western Australia
-
Nedlands, Western Australia, Australië, 6009
- Sir Charles Gairdner Hospital
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Cross Cancer Institute (University of Alberta)
-
-
British Columbia
-
Surrey, British Columbia, Canada, V1V 1Z2
- British Columbia Cancer Agency (BCCA) - Fraser Valley Cancer
-
Vancouver, British Columbia, Canada, V5Z 4E6
- BC Cancer Agency - Vancouver
-
-
Ontario
-
Oshawa, Ontario, Canada, L1G 2B9
- Lakeridge Health Oshawa
-
Ottawa, Ontario, Canada, K1H 8L6
- The Ottawa Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H3G 1A4
- Montreal General Hospital - McGill University Health Centre
-
-
-
-
-
Beijing, China, 100021
- Cancer Hospital of Chinese Academy of Medical Science
-
Beijing, China, 100036
- Beijing Cancer Hospital
-
Guangzhou, China, 510060
- Sun Yat-sen University Cancer Center
-
Nan Ning, China, 530021
- The Affiliated Cancer Hospital, Guangxi Medical University
-
Shanghai, China, 200030
- Shanghai Chest Hospital
-
Shanghai, China, 200032
- Zhongshan Hospital Fudan University
-
Shenyang, China, 110001
- The First Hospital of Chinese Medical University
-
-
-
-
-
Essen, Duitsland, 45122
- Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
-
Esslingen, Duitsland, 73730
- Klinikum Esslingen GmbH
-
Mainz, Duitsland, 55131
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz
-
-
-
-
-
Bayonne, Frankrijk, 64100
- CTR Oncologie du Pays Basque, Onco, Bayonne
-
Caen, Frankrijk, 14076
- CTR François Baclesse
-
Créteil, Frankrijk, 94010
- HOP Intercommunal
-
La Tronche, Frankrijk, 38700
- HOP Michallon
-
Limoges Cedex, Frankrijk, 87042
- HOP Dupuytren 1
-
Lyon, Frankrijk, 69373
- CTR Leon Berard
-
Saint Herblain, Frankrijk, 44805
- CTR René Gauducheau
-
St-Pierre - La Réunion, Frankrijk, 97448
- HOP Sud-Réunion, Pneumo, Saint Pierre
-
-
-
-
-
Hongkong, Hongkong
- Queen Mary Hospital
-
Shatin, Hongkong
- Prince of Wales Hospital
-
-
-
-
-
Dublin, Ierland, 8
- St James's Hospital
-
Dublin 9, Ierland, D09 Y5R3
- Beaumont Hospital
-
-
-
-
-
Cheongju, Korea, republiek van, 361-771
- Chungbuk National University Hospital
-
Incheon, Korea, republiek van, 405-760
- Gachon University Gil Medical Center
-
Seoul, Korea, republiek van, 135-710
- Samsung Medical Center
-
Seoul, Korea, republiek van, 138-736
- Asan Medical Center
-
Seoul, Korea, republiek van, 110-744
- Seoul National University Hospital
-
Seoul, Korea, republiek van, 120-752
- Severance Hospital
-
-
-
-
-
Oslo, Noorwegen, N-0379
- Oslo Universitetssykehus HF, Radiumhospitalet
-
-
-
-
-
Singapore, Singapore, 308433
- Johns Hopkins Singapore International Medical Center
-
Singapore, Singapore, 169610
- National Cancer Centre
-
-
-
-
-
Madrid, Spanje, 28041
- Hospital Universitario 12 de Octubre
-
Malaga, Spanje, 29010
- Hospital Regional Universitario de Málaga
-
Oviedo, Spanje, 33006
- Hospital Central de Asturias
-
Santander, Spanje, 39008
- Hospital Universitario Marques de Valdecilla
-
Sevilla, Spanje, 41013
- Hospital Virgen del Rocio
-
-
-
-
-
Taichung, Taiwan, 407
- Taichung Veterans General Hospital
-
Tainan, Taiwan, 704
- NCKUH
-
Taipei, Taiwan, 100
- National Taiwan University Hospital
-
Taipei, Taiwan, 112
- Taipe Veterans General Hospital
-
Tao-Yuan, Taiwan, 333
- Chang Gung Memorial Hospital(Linkou)
-
-
-
-
-
Aberdeen, Verenigd Koninkrijk, AB25 2ZN
- Aberdeen Royal Infirmary
-
Birmingham, Verenigd Koninkrijk, B18 7QH
- Birmingham City Hospital
-
Cardiff, Verenigd Koninkrijk, CF14 2TL
- Velindre Cancer Centre
-
Edinburgh, Verenigd Koninkrijk, EH4 2XU
- Western General Hospital
-
Guildford, Verenigd Koninkrijk, GU2 7XX
- Royal Surrey County Hospital
-
-
-
-
-
Göteborg, Zweden, 413 45
- Sahlgrenska US, Göteborg
-
Linköping, Zweden, 581 85
- Universitetssjukhuset, Linköping
-
Lund, Zweden, 221 85
- Skånes universitetssjukhus, Lund
-
Stockholm, Zweden, 171 76
- Karolinska Univ. sjukhuset
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar tot 90 jaar (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion criteria:
- Pathologically confirmed diagnosis of Stage IIIB / IV adenocarcinoma of the lung.
- Documented activating epidermal growth factor receptor mutation (Del19 and/or L858R) with tumour tissues.
- At least one measurable lesion according to response evaluation criteria in solid tumours version 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Age >= 18 years.
- Adequate organ function as defined by the following criteria:
Serum aspartate transaminase(AST) and serum alanine transaminase(ALT) =< 3 x upper limit of normal (ULN), or AST and ALT =<5 x ULN if liver function abnormalities are due to underlying malignancy Total serum bilirubin =<1.5 x ULN Absolute neutrophil count (ANC) >=1.5 x 109/L Creatinine clearance > 45ml / min Platelets >= 75 x 109/L
Exclusion criteria:
- Prior systemic chemotherapy for stage IIIB or IV non-small cell lung cancer. Neo-/adjuvant chemotherapy, chemoradiation or radiotherapy is permitted if at least 12 months has elapsed prior to disease progression.
- Prior treatment with epidermal growth factor receptor targeting small molecules or antibodies.
- Major surgery within 4 weeks of study randomisation.
- Active brain metastases
- Meningeal carcinomatosis.
- Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured in the opinion of investigator.
- Known pre-existing interstitial lung disease.
- Clinically relevant cardiovascular abnormalities as judged by the investigator.
- Cardiac left ventricular function with resting ejection fraction of less than institutional lower limit of normal.
- Women of child-bearing potential (WOCBP) and men who are able to father a child, unwilling to be abstinent or use adequate contraception prior to study entry, for the duration of study participation and for at least 2 months after treatment has ended.
- Pregnancy or breast-feeding.
- Active hepatitis and/or known HIV carrier
- Any prohibited concomitant medications for therapy with afatinib or gefitinib
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: afatinib
afatinib once daily.
|
afatinib once daily
Andere namen:
|
|
Actieve vergelijker: gefitinib
gefitinib once daily
|
Gefitinib once daily
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-free Survival
Tijdsspanne: From first drug administration until 28 days after last drug administration + Follow-Up period for collecting information on disease progression or death, up to 2465 days.
|
Progression-free survival (PFS) defined as the time from date of randomisation to date of disease progression, or date of death if a patient died earlier.
Participants with no event (Disease progression (PD) or death) were censored.
PD was primarily evaluated for the primary analysis by an independent central imaging review according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.
Per RECIST version 1.1.
for target lesions and assessed by Computed Tomography (CT)-scan or Magnetic Resonance Imaging (MRI): PD, At least a 20% increase in the sum of the longest diameter (SoD) of target lesions taking as reference the smallest SoD of target lesions recorded since the treatment started, together with an absolute increase in the SoD of target lesions of at least 5 millimetre (mm) or the appearance of one or more new lesions.
For the final analysis (analysis cut-off date 12 April 2019) status and date of PD were determined by investigator assessment.
|
From first drug administration until 28 days after last drug administration + Follow-Up period for collecting information on disease progression or death, up to 2465 days.
|
|
Time to Treatment Failure (TTF) (Main Overall Survival Analysis Cut-off Date, 08 April 2016)
Tijdsspanne: From first drug administration until last drug administration, up to 1482 days
|
Time to Treatment Failure (TTF) which was the time from the date of randomisation to the date of i.e. permanent treatment discontinuation for any reason.
|
From first drug administration until last drug administration, up to 1482 days
|
|
Overall Survival
Tijdsspanne: From first drug administration until 28 days after last drug administration + Follow-Up period for collecting information on death, up to 2465 days.
|
Overall survival (OS) which was defined as the time from the date of randomisation to the date of death.
Participants for whom there is no evidence of death at the time of the analysis will be censored at the date that they were last known to be alive.
|
From first drug administration until 28 days after last drug administration + Follow-Up period for collecting information on death, up to 2465 days.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Objective Response Rate
Tijdsspanne: From first drug administration until 28 days after last drug administration + Follow-Up period for collecting information on disease progression, further anti-cancer treatment and death, up to 2465 days.
|
Objective response rate (ORR) which was defined as the number of participants with best overall response of complete response (CR) or partial response (PR) as assessed by central independent review according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.
divided by the total number of participants who received treatment.
Per RECIST version 1.1.
for target lesions and assessed by Computed Tomography (CT)-scan or Magnetic Resonance Imaging (MRI): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions from baseline.
For the final analysis (analysis cut-off date 12 April 2019) objective response was determined by investigator assessment.
|
From first drug administration until 28 days after last drug administration + Follow-Up period for collecting information on disease progression, further anti-cancer treatment and death, up to 2465 days.
|
|
Time to Objective Response
Tijdsspanne: From first drug administration until 28 days after last drug administration + Follow-Up period for collecting information on disease progression, further anti-cancer treatment and death, up to 2465 days.
|
Number of participants with objective response (best overall response of complete response or partial response) to study treatment over time, cumulative number of participants is displayed.
Time to objective response was defined as the time from randomisation to the first recorded objective response.
For the final analysis (analysis cut-off date 12 April 2019) objective response was determined by investigator assessment.
|
From first drug administration until 28 days after last drug administration + Follow-Up period for collecting information on disease progression, further anti-cancer treatment and death, up to 2465 days.
|
|
Duration of Objective Response
Tijdsspanne: From first drug administration until 28 days after last drug administration + Follow-Up period for collecting information on disease progression, further anti-cancer treatment and death, up to 2465 days.
|
Duration of objective response defined as the time of first objective response (best overall response of complete response or partial response) to the time of progression or death, whichever occurred first (or date of censoring for progression free survival).
For the final analysis (analysis cut-off date 12 April 2019) objective response was determined by investigator assessment.
|
From first drug administration until 28 days after last drug administration + Follow-Up period for collecting information on disease progression, further anti-cancer treatment and death, up to 2465 days.
|
|
Disease Control
Tijdsspanne: From first drug administration until 28 days after last drug administration + Follow-Up period for collecting information on disease progression or death, up to 2465 days.
|
Percentage of participants with disease control which was defined as the number of participants with best overall response of complete response (CR) or partial response (PR) or stable disease (SD) as assessed by central independent review according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.
divided by the total number of participants who received treatment.
Per RECIST version 1.1.
for target lesions and assessed by Computed Tomography (CT)-scan or Magnetic Resonance Imaging (MRI): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions from baseline; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Responses of SD were only considered if they occur ≥42 days from date of randomisation.
For the final analysis (analysis cut-off date 12 April 2019) disease control was determined by investigator assessment.
|
From first drug administration until 28 days after last drug administration + Follow-Up period for collecting information on disease progression or death, up to 2465 days.
|
|
Duration of Disease Control
Tijdsspanne: From first drug administration until 28 days after last drug administration + Follow-Up period for collecting information on disease progression or death, up to 2465 days.
|
Duration of disease control defined as the time from randomisation to the time of progression or death, whichever occurred first (or date of censoring for progression free survival).
For the final analysis (analysis cut-off date 12 April 2019) the status and date of disease progression were determined by investigator assessment.
|
From first drug administration until 28 days after last drug administration + Follow-Up period for collecting information on disease progression or death, up to 2465 days.
|
|
Tumour Shrinkage (Main Overall Survival Analysis Cut-off Date, 08 April 2016)
Tijdsspanne: From first drug administration until last drug administration, up to 1482 days
|
Tumour shrinkage assessed by minimum sum of post-baseline target lesion diameters recorded after randomisation.
A positive value shows a decrease in tumour size.
|
From first drug administration until last drug administration, up to 1482 days
|
|
Health-related Quality of Life (Primary Analysis Cut-off Date, 21 August 2015)
Tijdsspanne: Every 8 weeks, up to 56 weeks
|
Health-related quality of life (HRQoL) measured using European Quality of life - 5 Dimensions (EQ-5D) score for United Kingdom (UK) and Belgium and European European Quality Visual Analogue Scale (EQ-VAS). EQ-5D utility scores range from 0 (worst health) to 1 (full health). EQ-VAS scores range from 0 (worst imaginable health state) to 100 (best imaginable health state). Results display the mean score up to 56 weeks. |
Every 8 weeks, up to 56 weeks
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Algemene publicaties
- Wu YL, Sequist LV, Tan EH, Geater SL, Orlov S, Zhang L, Lee KH, Tsai CM, Kato T, Barrios CH, Schuler M, Hirsh V, Yamamoto N, O'Byrne K, Boyer M, Mok T, Peil B, Marten A, Chih-Hsin Yang J, Paz-Ares L, Park K. Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. Clin Lung Cancer. 2018 Jul;19(4):e465-e479. doi: 10.1016/j.cllc.2018.03.009. Epub 2018 Mar 17.
- Paz-Ares L, Tan EH, O'Byrne K, Zhang L, Hirsh V, Boyer M, Yang JC, Mok T, Lee KH, Lu S, Shi Y, Lee DH, Laskin J, Kim DW, Laurie SA, Kolbeck K, Fan J, Dodd N, Marten A, Park K. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol. 2017 Feb 1;28(2):270-277. doi: 10.1093/annonc/mdw611.
- Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kolbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 May;17(5):577-89. doi: 10.1016/S1470-2045(16)30033-X. Epub 2016 Apr 12.
Nuttige links
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
13 december 2011
Primaire voltooiing (Werkelijk)
8 april 2016
Studie voltooiing (Werkelijk)
12 april 2019
Studieregistratiedata
Eerst ingediend
4 november 2011
Eerst ingediend dat voldeed aan de QC-criteria
4 november 2011
Eerst geplaatst (Schatting)
8 november 2011
Updates van studierecords
Laatste update geplaatst (Werkelijk)
7 april 2020
Laatste update ingediend die voldeed aan QC-criteria
26 maart 2020
Laatst geverifieerd
1 maart 2020
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Ziekten van de luchtwegen
- Neoplasmata per histologisch type
- Neoplasmata
- Longziekten
- Neoplasmata per site
- Carcinoom
- Neoplasmata, glandulair en epitheel
- Neoplasmata van de luchtwegen
- Thoracale neoplasmata
- Longneoplasmata
- Adenocarcinoom
- Adenocarcinoom van de longen
- Moleculaire mechanismen van farmacologische werking
- Enzymremmers
- Antineoplastische middelen
- Proteïnekinaseremmers
- Gefitinib
- Afatinib
Andere studie-ID-nummers
- 1200.123
- 2011-001814-33 (EudraCT-nummer)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .